316P - Treatment and rehabilitation of hydatidiform Mole (316P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Cancer and Pregnancy
Cancer in Special Situations
Gynaecological Malignancies
Presenter Tengiz Carkviani
Citation Annals of Oncology (2017) 28 (suppl_10): x86-x93. 10.1093/annonc/mdx663
Authors T. Tsintsadze, T. Carkviani, L. Metonidze, I. Dvalishvili, S. Carkviani
  • Gynaecological, Oncological National Centre of Georgia, 0186. - Tbilisi/GE

Abstract

Background

In 1977-2016 total 590 patients with hydatidiform mole applied to the Center. Main associated pathologies revealed were thyroid gland diseases: goiter 51%, thyroiditis 43.6%, share of other somatic diseases was minimum.

Methods

Hydatidiform mole treatment was performed according to the developed scheme. Chemotherapy was applied in 81.4% of cases (mono – 94.5%, polychemotherapy – 5.4%, complex – 5.5%), preparations doses and duration of treatment depended on hydatidiform mole.

Results

In 1977-2016 total 590 patients with hydatidiform mole applied to the Center. Of them 81.7% had non-invasive and 18.3% invasive mole. Anamnesis showed that in most cases (70.7%) menses started in time at the age of 12-16, sexual life at the age of 16-30 (89.6%), respectively the first delivery was timely at the age of 16-30 (74.2%). Neither frequent deliveries (5>2/1%) not frequent abortions (3-7%) were characteristic for these patients. Main associated pathologies revealed were thyroid gland diseases: goiter (51%), thyroiditis (43.6%), share of other somatic diseases was minimum. Dynamic testing of chorionic gonadotophin level in blood showed that in 46.4% of cases βCHG level was increased. With non-invasive hydatidiform mole these results ranged between 27.4% (simple) and 54.8% (prolipherative) and in the case of invasive form in 73.1%. Ultrasound in dynamics detected existence of lutein ovarian cysts 29.8%, after treatment their number reduced almost seven times to 4.1%. Hydatidiform mole treatment was performed according to the developed scheme. Due to normal level of βCHG and simple form of disease, treatment was not performed and no recurrence occurred. Chemotherapy was applied in 81.4% of cases (mono 94.5%, polychemotherapy 5.4%, complex 5.5%), preparations doses and duration of treatment depended on hydatidiform mole.

Conclusions

Following the developed scheme of hydatidiform mole treatment-rehabilitation maximum positive results were achieved.5% of women of childbearing age had mature live-births, which demonstrates the optimization of tactics.

Clinical trial identification

In 1977-2016 total 590 patients with hydatidiform mole applied to the Center. Of them 81.7% had non-invasive and 18.3% invasive mole.Anamnesis showed that in most cases (70.7%) menses started in time at the age of 12-16, sexual life at the age of 16-30 (89.6%), respectively the first delivery was timely at the age of 16-30 (74.2%). Neither frequent deliveries (5>2/1%) not frequent abortions (3-7%) were characteristic for these patients.Main associated pathologies revealed were thyroid gland diseases: goiter (51%), thyroiditis (43.6%), share of other somatic diseases was minimum.Dynamic testing of chorionic gonadotophin level in blood showed that in 46.4% of cases βCHG level was increased. With non-invasive hydatidiform mole these results ranged between 27.4% (simple) and 54.8% (prolipherative) and in the case of invasive form in 73.1%.Ultrasound in dynamics detected existence of lutein ovarian cysts 29.8%, after treatment their number reduced almost seven times to 4.1%.Hydatidiform mole treatment was performed according to the developed scheme. Due to normal level of βCHG and simple form of disease, treatment was not performed and no recurrence occurred. Chemotherapy was applied in 81.4% of cases (mono 94.5%, polychemotherapy 5.4%, complex 5.5%), preparations doses and duration of treatment depended on hydatidiform mole.Following the developed scheme of hydatidiform mole treatment-rehabilitation maximum positive results were achieved.5% of women of childbearing age had mature live-births, what evidences the optimization of tactics.

Legal entity responsible for the study

Prof. R. Ghvamichava Director, Universal Medical Centre - National Oncology Centre

Funding

None

Disclosure

All authors have declared no conflicts of interest.